Sanofi’s Inhibrx INBX Stock Holding History

Sanofi’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110M	Hold	1,157,926	–	–	20.54%	2
2026 Q1	$77.8M	Hold	1,157,926	–	–	23.17%	2
2025 Q4	$91.5M	Hold	1,157,926	–	–	29.47%	2
2025 Q3	$39M	Hold	1,157,926	–	–	14.98%	3
2025 Q2	$16.5M	Hold	1,157,926	–	–	9.4%	4
2025 Q1	$16.2M	Hold	1,157,926	–	–	9.76%	3
2024 Q4	$17.8M	Buy	+1,157,926	New	+$17.6M	10.23%	3

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Sanofi's INBX Position: Q2 2026 in Review

Sanofi held its Inhibrx (INBX) position steady in Q2 2026 at 1,157,926 shares worth $110M. The position accounts for 20.54% of the portfolio, ranked #2.

Sanofi first reported a position in INBX in Q4 2024 and has held it in 7 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Sanofi held 1,157,926 shares of Inhibrx worth $110M as of Q2 2026.
Sanofi left its Inhibrx share count unchanged in Q2 2026.
Inhibrx made up 20.54% of Sanofi's portfolio in Q2 2026, its #2 holding.
Sanofi first reported a position in Inhibrx in Q4 2024 and has held it in 7 quarters since.
163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Sanofi's 13F filing for Q2 2026, filed 28 Jul 2026.